Benzinga

Benzinga

Benzinga

mercoledì, agosto 19

Edwards Lifesciences Corp

EWNYSE
Trade with Public
Trade with Public
$90.98
0.170.19%
In chiusura: Aug 17, 5:00 PM EST
$90.98
0.170.19%
Pre-mercato: 4:46 AM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaOpzioniRapporto azionario

Edwards Lifesciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Edwards Lifesciences (EW).

Price Target Range — 8 Quarters

Analyst Consensus — 20 Analysts

17Buy
3Hold
Consensus RatingBuy# Analysts20Avg. Consensus PT$100Upside to Avg. PT+9.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jul 28, 2026UBSPatrick WoodAssumesNeutral→Buy$110
Jul 24, 2026Leerink PartnersMike KratkyUpgradeMarket Perform→Outperform$87→$101
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Edwards Lifesciences, Raises Price Target to $105

JP Morgan analyst Robbie Marcus maintains Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $100 to $105.
Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on Edwards Lifesciences, Raises Price Target to $101

Piper Sandler analyst Adam Maeder reiterates Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $100 to $101.
Benzinga Newsdesk

Edwards Earnings Add Fuel To Bullish MedTech Thesis, Analyst Says

Edwards Lifesciences tops Q2 Wall Street estimates with $1.74B in revenue. EW stock jumps as analysts see continued upside ahead.
Vandana Singh

PRO
Truist Securities Maintains Hold on Edwards Lifesciences, Raises Price Target to $95

Truist Securities analyst Richard Newitter maintains Edwards Lifesciences (NYSE:EW) with a Hold and raises the price target from $90 to $95.
Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Edwards Lifesciences, Raises Price Target to $105

Mizuho analyst Anthony Petrone maintains Edwards Lifesciences (NYSE:EW) with a Outperform and raises the price target from $100 to $105.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Edwards Lifesciences, Raises Price Target to $110

RBC Capital analyst Shagun Singh maintains Edwards Lifesciences (NYSE:EW) with a Outperform and raises the price target from $100 to $110.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved